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RESEARCH ARTICLE Open Access
Triple negative breast cancers express receptors
for LHRH and are potential therapeutic targets for
cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
Stephan Seitz1, Stefan Buchholz1, Andrew Victor Schally2,3, Florian Weber4, Monika Klinkhammer-Schalke5,
Elisabeth C Inwald1, Roberto Perez2, Ferenc G Rick6, Luca Szalontay2, Florian Hohla7, Sabine Segerer8,
Chui Wai Kwok1, Olaf Ortmann1 and Jörg Bernhard Engel9*
Abstract
Background: Triple negative breast cancer (TNBC) is a distinct subtype of breast cancer burdened with a dismal
prognosis due to the lack of effective therapeutic agents. Receptors for LHRH (luteinizing hormone-releasing
hormone) can be successfully targeted with AEZS-108 [AN-152], an analog of LHRH conjugated to doxorubicin.
Our study evaluates the presence of this target LHRH receptor in human specimens of TNBC and investigates
the efficacy and toxicity of AEZS-108 in vivo. We also studied in vitro activity of AEZS-125, a new LHRH analog
conjugated with the highly potent natural compound, Disorazol Z.
Methods: 69 human surgical specimens of TNBC were investigated for LHRH-R expression by immunohistochemistry.
Expression of LHRH-R in two TNBC cell lines was evaluated by real time RT-PCR. Cytotoxicity of AEZS-125 was evaluated
by Cell Titer Blue cytoxicity assay. LHRH- receptor expression was silenced with an siRNA in both cell lines. For the
in vivo experiments an athymic nude mice model xenotransplanted with the cell lines, MDA-MB-231 and HCC 1806,
was used. The animals were randomised to three groups receiving solvent only (d 1, 7, 14, i.v.) for control, AEZS-108
(d 1, 7, 14, i.v.) or doxorubicin at an equimolar dose (d 1, 7, 14, i.v.).
Results: In human clinical specimens of TNBC, expression of the LHRH-receptor was present in 49% (n = 69).
HCC 1806 and MDA-MB-231 TNBC cells expressed mRNA for the LHRH-receptor. Silencing of the LHRH-receptor
significantly decreased the cytotoxic effect of AEZS-108. MDA-MB-231 and HCC 1806 tumors xenografted into
nude mice were significantly inhibited by treatment with AEZS-108; doxorubicin at equimolar doses was ineffective.
As compared to AEZS 108, the Disorazol Z – LHRH conjugate, AEZS-125, demonstrated an increased cytotoxicity in vitro
in HCC 1806 and MDA-MB-231 TNBC; this was diminished by receptor blockade with synthetic LHRH agonist (triptorelin)
pretreatment.
Conclusion: The current study confirms that LHRH-receptors are expressed by a significant proportion of TNBC and can
be successfully used as homing sites for cytotoxic analogs of LHRH, such as AEZS-108 and AEZS-125.
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* Correspondence: joergbengel@hotmail.com
9Depertment of Obsteterics and Gynecology, Medical University of Gießen,
35392 Gießen, Germany
Full list of author information is available at the end of the article
© 2014 Seitz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Seitz et al. BMC Cancer 2014, 14:847
http://www.biomedcentral.com/1471-2407/14/847
Background
The hypothesis of a ‘magic bullet’ that could specifically
eradicate cancers was conceived in 1898 by Paul Ehrlich,
but remained undeveloped for decades. Following the
discovery that tumor cells express certain specific extra-
or intracellular proteins, the concept of using receptor
proteins as potential targets for “magic bullets” became
applicable to tumor therapy [1].
Breast cancer is a heterogeneous disease that encom-
passes several distinct entities with different biological
characteristics and clinical behaviors. Currently, breast
cancer patients are treated by approaches based on vari-
ous clinical parameters in conjunction with assessment
of the status of sex steroid receptors (estrogen and pro-
gesterone receptors) and the overexpression of HER2.
Although effective endocrinologically tailored therapies
have been developed for patients with hormone receptor-
positive or HER2-positive disease, at present chemother-
apy is the only modality of systemic therapy for patients
with triple-negative breast cancers.
The definition of triple-negative breast cancer (TNBC)
refers to a group of tumors, which do not express recep-
tors for estrogen or progesterone and which do not
overexpress the HER2 receptor. Tumors belonging to
this subgroup often are of the basal-like subtype, i.e. they
express genes that are characteristic of basal epithelial
cells. However, not all TNBC are basal-cell like tumors,
therefore these two expressions are not used as syno-
nyms. TNBCs show distinctive clinical features and
account for 10–17% of all breast carcinomas [2,3].
TNBCs tend to more frequently affect younger patients
[4], are more prevalent in African Americans, [5] and are
clinically more aggressive than tumors belonging to the
other known clinical subgroups [2,3,6,7]. As TNBCs do
not express the potential therapeutic targets mentioned
above (i.e. receptors for estrogen, progesterone or HER2)
targeted therapy has not been possible and chemotherapy
has been the only therapeutic option for these patients.
Although TNBCs are sensitive to chemotherapy [2], the
response rates are low, the prognosis remains poor. Thus,
in patients with TNBC disease recurrence occurs earlier
and most deaths occur in the first five years after diagnosis
[3,8]. These observations underline the importance of
identifying specific therapeutic targets for this breast can-
cer subgroup.
Specific receptors for LHRH were originally detected
in the pituitary gland, but were also described in healthy
tissue of male and female reproductive organs. They
expressed only at low levels or not at all by other, be-
nign, tissues. Strikingly, these receptors have also been
detected on a variety of human cancer cells, such as
breast, prostatic, ovarian and endometrial, making them
suitable targets for specific targeted tumor therapy [9-19].
Predicated on these findings, a new class of antitumor
compounds based on LHRH has been developed for tar-
geted chemotherapy. In this approach agonists or antago-
nists of LHRH are used as carriers to deliver cytotoxic
agents directly to cancerous cells, thereby increasing the
local concentration of the cytotoxic drug in the tumor tis-
sue while sparing normal, non-cancerous cells from un-
necessary damage [20]. In recent years, cytotoxic analogs
of various peptides containing doxorubicin have been de-
veloped. AEZS-108 (also known as AN-152) is such a
cytotoxic hybrid molecule and consists of doxorubicin
linked to the LHRH agonist, [D-Lys6] LHRH [17,19-21].
A pilot study, performed by our group, demonstrated,
by immunohistochemistry, RT-PCR, and Western blot
analysis, that LHRH receptors are expressed on TNBC
tissues. However, only 17 tumor specimens were ana-
lysed in this study [22].
In the current study a larger TNBC specimen group is
analyzed with respect to LHRH receptor expression and
a possible correlation with clinical stage and histopatho-
logical parameters. Additionally, the efficacy and toxicity
of cytotoxic LHRH analog, AEZS-108, is tested in two
models of TNBC in vivo.
The LHRH receptor targeting concept offers the possibil-
ity of replacing doxorubicin with even more potent cyto-
toxics, but with the advantage of increasing anticancer
activity without enhancing organ toxicity. Thus, doxorubicin
in AEZS-108 was replaced by Disorazol Z which was iso-
lated from myxo-bacteria and which has anti-proliferative
activity in the pico to low nano-molar range [23]. The cyto-
toxic potency of AEZS-125 was confirmed in two TNBC
models in vitro and its LHRH receptor targeting was con-
firmed by competition experiments with the LHRH agonist,
triptorelin.
Methods
Peptides and cytotoxic radicals
Cytotoxic LHRH-conjugate, AEZS-108, was originally
synthesized in our laboratory (AVS) by coupling one
molecule of doxorubicin-14-O-hemiglutarate to the
ε-amino group of the D-Lys side chain of the carrier
peptide [D-Lys6] LHRH [17,21]. The batch of AEZS-
108 used for this work was provided by Aeterna-Zentaris.
Cytotoxic doxorubicin hydrochloride was obtained from
Chemex Export–import Gmbh (Vienna, Austria). Be-
fore intravenous (i.v.) injection, the compounds were
dissolved in 5% (w/v) aqueous D-mannitol solution (Sigma,
St Louis, MO).
AEZS-125 and Disorazol Z was kindly provided by
Dr. Michael Teifel, Aeterna-Zentaris GmbH, Frankfurt,
Germany.
Cell lines
HCC 1806 and MDA-MB-231 triple negative human breast
cancer cell lines were obtained from American Type
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Culture Collection (Bethesda, MD). HCC 1806 cells
were grown in RPMI 1640 cell culture medium (ATCC
Bethesda, MD) supplemented with 10% FBS and anti-
biotics in an 95% Air/5% CO2 atmosphere at 37°C.
MDA-MB-231 cells were cultured in the Dubecco’s modi-
fied essential medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and penicillin/streptomycin
at 371 C and 5% CO2 atmosphere. Chemicals, unless
stated otherwise, were purchased from Sigma (St. Louis,
Missouri, USA).
Screening of HCC1806 and MDA-MB231 cells for receptor
expression
Cells of HCC1806 human TNBC were cultured in flat
bottom tissue culture plates using adherent conditions.
Cells were collected from adherent cultures using trypsin
dissociation. Cells were counted using a hemocytometer
and trypan blue exclusion assay. Approximately 1.0 × 106
cells were centrifuged and used for RNA isolation.
RNA isolation was performed with the GE Illustra
RNA isolation kit as recommended by the manufacturer.
RNA was quantified using a nanodrop spectrophotom-
eter and 100 ng used for the analysis of LHRH (also
known as GnRH), LHRH-R (also known as GnRH-R),
ESR, Her2, and PgR expression with the Bio-Rad One-
Step RT-PCR with SYBR kit. (Table 1) All reactions were
performed with the Bio-rad CFX real-time PCR system.
Normalization of gene expression was conducted using
the geometric mean of the relative quantities of actβ and
GAPDH (δδCt method, appendix 1). Human pituitary
RNA and human fibroblast RNA was used as positive
controls for all reactions. Mouse skin RNA was used as
negative control for all reactions since our primers were
designed to strictly match only the human sequences.
The real-time RT-PCR program consisted of a 30 minute
reverse-transcription at 52°C followed by a simultaneous
reverse transcriptase inactivation and polymerase acti-
vation at 95°C for 10 minutes. Once the polymerase
was activated, the samples were subjected to 40 cycles
of 2-stage PCR following the sequence of denaturing
at 95°C, 10 seconds and annealing/extension at 57°C,
15 seconds. Melting curve analysis confirmed that the
real-time RT-PCR resulted in only one product for
each reaction and in no primer dimerization.
PCR reaction products were electrophoresed on a 2%
agarose gel using 60 V for 100 minutes. Loading buffer
was used which contained a final concetration of 2X
SYBR green I DNA binding dye for visualization of the
resulting bands.
Fluorescent labeling of LHRHR on HCC1806 and
MDA-MB-231 cells
Cells, cultured on sterile coverslips were used for im-
munofluorescent analysis. Specimens were incubated in
3% H2O2 in methanol for 5 minutes. Coverslips were
washed with PBS three times, permeabilized in 0.2%
Triton-X in PBS for 10 minutes and blocked with 2%
goat serum in PBS for 30 min. LHRHR antibody (1:100
dilution, abcam ab58561) was added in PBS for 1 h. This
was followed by 3 washes with PBS. Anti-goat secondary
antibody (Alexa Fluor 488; Jackson Immunoresearch)
was also applied for 1 h and then wahsed 3 times. Primary
antibodies were applied for 30 minutes and fluorescent
secondary antibodies (green) for 20 minutes. Coverslips
were mounted in Vectashield mounting medium contain-
ing DAPI for nuclear staining (Vector Laboratories).
Images were acquired on a Nikon Eclipse Ti fluores-
cence microscope (Nikon Instruments). Samples were
mounted using standard optically clear mount medium.
Cells are contrasted with DAPI-stained nuclei (blue).
In vitro cell proliferation assay
The anti-proliferation effects of the toxic agent, Disorazol-Z,
and its LHRH conjugate, AEZS-125, were investigated in
the TNBC cell lines HCC1806 and MDA-MB-231.
Table 1 Sequence information for the oligonucleotide primers used for real-time RT-PCR analysis
Primer name Accession Number Prod Len Prod Tm 5′-Sense Primer-3′ Position 5′-Anti-sense Primer-3′ Position
Control
HS-rt-actB NM_001101 89 72.1 CCCACTTCTCTCTAAGGA 1,516 CATTACATAATTTACACGAAAGC 1,604
HS-rt-GAPDHv2 NM_002046 114 74.5 TGAGAAGTATGACAACAGC 513 ATGAGTCCTTCCACGATA 626
LHRH
HS-rt-LHRH NM_000825 77 70.5 CCTTTGTGGAAGTTATGTATG 410 CAGACCTATCAAGAGTTCAA 486
HS-rt-LHRHR NM_000406 75 70.7 GAATAACTATCCAGCACTCA 811 TTCAAATTGGGACCACTTA 885
HORMONE
HS-rt-ESR1 NM_000125 98 71.8 TTAGCCAAATTCTGTCTC 2,088 CACTAAGAACTGAGCAAG 2,185
HS-rt-HER2 NM_004448 98 71.4 AGCAATGGTGTCAGTATC 4,435 CCTGGGTCTTTATTTCATCT 4,532
HS-rt-PgR NM_000926 75 70.7 TTGGAAGGATGGCTATTAC 7,243 AAGGATAAGTATGGATGAGAG 7,317
Amplified target (amplicons) sequences were confirmed be sequencing.
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Cells were starved in 1% FBS containing DMEM/F12
two days before treatment with the LHRH analogs. They
were then trypsinized and counted 24 hours before
treatment. 7500 HCC1806 or 3000 MDA-MB-231 cells
were seeded in each well of a 96-well microplate with
100 μl serum free DMEM/F12. Three cultures of each
cell type were tested for each concentration and three
replicates were done for each of these.
Stock solutions of the compounds were made accord-
ing to the provider’s instructions and were stored in
10 μl aliquots at −20°C. On the day of treatment,
100 μM working solutions in serum and phenol red free
DMEM/F12 medium (Gibco, Darmstadt, Germany) were
prepared from the stock solutions. Twelve half-log dilu-
tions were done to produce a series of working solutions
with concentrations from 0.0001 μM to 100 μM. For
each well of the 96-well microplates, the contained
medium was changed to 150 μl serum and phenol red-
free DMEM/F12 supplemented with different concentra-
tions of the drugs, or with the DMSO, H2O or PBS used
as the solvent for the drugs.
After 48 hours, a cell titer blue (CTB) assay was per-
formed by addition of 15 μl CTB reagent (Promega,
Mannheim, Germany) to each well. The MDA-MB-231
and cells HCC1806 were then incubated under growth
conditions for 1 hours and 4 hour, respectively. The color
change and intensity of the CTB reagent was quantified
with the Wallac Victor™3 1420 Microlabel Counter
(Perkin Elmer, Rodgau, Germany) at a wavelength of
530 nm. The measured absorbance is proportional to
the number of viable cells. EC50 was determined by
the GraphPad Prism software (GraphPad, La Jolla, CA,
USA). Experiments were performed in triplicates and
repeated at least thrice.
LHRH receptor blocking experiments
To determine whether the anti-proliferative activity of
the Disorazol-Z LHRH conjugate AEZS-125 was medi-
ated by LHRH receptor, an LHRH receptor blocking and
competition study was carried out.
HCC1806 and MDA-MB-231 cells were starved and
seeded in 96-well plates as described. On the day of
treatment, the cells were incubated with 100 μM trip-
torelin or its solvent control, 1% DMSO, at 37°C for
10 minutes. After 10 minutes, the cells were washed
with PBS and incubated with 0 to 10 μM AEZS-125
for an additional 10 minutes. The cells were washed
again and cultivated in 150 μl serum and phenol red
free DMEM/F12 at 37°C with 5% CO2/95% air for
48 hours until accomplishing the CTB assay.
Small interfering RNA gene silencing
Silencing of LHRH-R was accomplished by reverse trans-
fection using the siPORT NeoFX Transfection Reagent
and Silencer Select siRNA (Applied Biosystems). Cells
were trypsinized immediately before silencing. Cell sus-
pensions were centrifuged at 3000 × g for 10 minutes and
the media removed. Cells were suspended to a density of
105 cells/ml in fresh media containing 10% FBS and anti-
biotic. RNA (1 μM) was diluted 1:4 in opti-MEM and
100 μl combined with 100 μl of 1:10 NeoFX solution per
well. Transfection complexes were allowed to form for
15 minutes at room temperature. In each well of a 48 well
culture plate, 250 μl of cell suspension was combined with
50 μl of complexes and cultured at 37°C and 5% CO2 for
72 hours, replacing the medium and transfection com-
plexes after this incubation period. Silenced cultures were
treated with either 500nM or 1 μM AeZS-108 for 72 hours
at which time the media was replaced and an MTS colori-
metric assay was used to determine proliferation relative
to the untreated controls.
Animals
Five- to six-week-old female athymic nude mice (Ncr nu/nu)
were obtained from the National Cancer Institute
(NCI, Bethesda, MD). The animals were housed in sterile
cages under laminar flow hoods in a temperature-controlled
room with a 12-h light/12-h dark schedule. They were fed
autoclaved chow and water ad libitum.
In vivo experiments
Cells of each cell line, growing exponentially, were im-
planted into 5 female donor nude mice by subcutaneous
injection of 3 × 106 cells into each flank. Tumors result-
ing after 4 weeks of growth were aseptically dissected
and mechanically minced. In all experiments, 3 mm3
pieces of tumor tissue were transplanted subcutaneously
(s.c.) into each experimental animal by trocar. Tumor
volume (length ×width × height × 0.5236) and body weight
were measured weekly.
At the end of each experiment, the mice were killed
under anesthesia, the tumors were excised and weighed,
and necropsy was performed. Tumor specimens were
snap frozen and stored at – 70 C. All experiments were
performed in accordance with the institutional guide-
lines for the welfare of animals in experiments.
In experiment 1, when the MDA-MB-231 tumors had
reached a volume of approximately 100 mm3, the mice
were divided into three experimental groups of 9–10 an-
imals each; each group received the following series of 3
injections on days 1, 8 and 15 into the jugular vein:
group 1, control, vehicle solution (5% mannitol), group 2,
cytotoxic analog AEZS-108 (2.5 mmol/kg) at a dose
equivalent to 1.45 mg/kg DOX, group 3, cytotoxic radical
DOX at 1.45 mg/kg. The experiment was terminated
on day 28.
In experiment 2, when HCC 1806 tumors had grown
to a volume of approximately 100 mm3, mice were
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assigned to three experimental groups of 5–6 animals
each; each group received the following series of 3 injec-
tions on days 1, 8 and 15 injection into the jugular vein:
group 1, control, vehicle solution, group 2, cytotoxic
analog AEZS-108 (2.5 mmol/kg) at a dose equivalent to
1.45 mg/kg DOX, group 3, cytotoxic radical DOX at
1.45 mg/kg. The experiment was terminated on day 28.
The Institutional Animal Care and Use Committee
(Medical Research Service of the Veterans Affairs Depart-
ment) reviewed the protocol for the animal experiments
and gave full approval. All the procedures in vivo were in
accordance with UKCCCR guidelines for the welfare of
animals in experimental neoplasia.
Human specimens and detection of LHRH receptors by
immunohistochemistry and clinical data set
Tumor samples and data were collected at the Tumor
Center Regensburg a high quality population-based re-
gional cancer registry covering a population of more
than 2.2 million people of the districts of Upper Palatinate
and Lower Bavaria and the University of Regensburg
(Department of Gynecology and Obstetrics, Department
of Pathology) following institutional guidelines and
approval from the ethics committee of the University
of Regensburg. Written informed consent for sample
collection was obtained from all patients.
For immunohistochemistry, sections (4 to 5 μm thick)
of tissue microarrays with probes of a total of 69 patients
with confirmed TNBC were incubated with an antibody
against LHRH receptor (Anti-GnRHR antibody A9E4,
Abcam, UK) after previous antigen retrieval (3-min passages
in a microwave oven at 750 watts in 10 mmol/l citrate buffer
pH 6.0) at a dilution of 1:1500 for 30 min at room
temperature. After drying overnight at 37°C, the EnVi-
sion combined peroxidase/diaminobenzidine detection
system (Dako, Germany) was applied for visualization.
The available clinical data set was evaluated by grade,
tumor size, and nodal status according to the WHO/
TNM classification system and the histological subtype.
Statistical analysis
For statistical analysis, Student’s two tailed t-test was
used. A p value of less than 0.05 was considered as
significant.
Results
Screening of HCC1806 and MDA-MB231 cells for receptor
expression
HCC1806 and MDA-MB231 cells were found to express
LHRH-R but not LHRH (Figure 1). Additionally, our
analysis confirms that both cell-lines are TNBC and do
not express ER nor PgR and do not overexpress Her2.
Additionally, LHRH-receptors were demonstrated by
fluorescent labeling on HCC-1806 and MDA-MB-231
cells (Figure 2 a,b).
Inhibition of TNBC cell proliferation by the LHRH
conjugate AEZS-125
AEZS-125 is an LHRH conjugate with the cytotoxic
drug, Disorazol-Z, and was found to be potent in inhibiting
cell proliferation in TNBC cells (Figure 3 a,b). Disorazol-Z
inhibited cell proliferation at low nanomolar concentra-
tions. As expected, the hybrid cytotoxic compound AEZS-
125 displayed lower cytotoxic effect in vitro than Disorazol,
being the larger molecule. Doxorubicin and its cytotoxic
conjugate, AEZS-108, also displayed significant cytoxicity
in MDA-MB-231 cells (Figure 3c). As expected in an in vitro
assay, the smaller molecule doxorubin was more cytotoxic
than the conjugate. With an EC 50 in the low micromolar
range AEZS-108 is the weaker cytotoxic agent as compared
to AEZS-125. In order to show receptor mediated uptake
of AEZS-125, LHRH- receptor blocking experiments
with the LHRH analog, triptorelin, were performed
(Figure 4).
LHRH receptor mediated anti-proliferation activities of
AEZS-125
In the control cell line LTK (−), which does not express
any LHRH receptor, no reduction of the anti-proliferation
activity of AEZS-125 was detected when the cells were
pretreated with 100 μM triptorelin (Figure 2). This finding
illustrated that triptorelin does not have any competitive
effect with AEZS-125 in the absence of the LHRH recep-
tor. In other words, the cell growth inhibitory effect of
AEZS-125 observed with LTK (−) cells was LHRH recep-
tor independent. On the other hand, the anti-proliferation
effects of AEZS-125 in triptorelin pretreated HCC1806
Figure 1 PCR reaction products were electrophoresed on a 2%
agarose gel using 60 V for 100 minutes. Real-time one step RT-PCR
analysis indicates that both HCC1806 and MDA-MB231 express LHRH-R.
Human fibroblasts and human pituitary RNA were used as positive
controls and mouse skin RNA was used as a species specificity control.
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Figure 2 Fluorescent micrograph of MDA-MB-231 (a) and HCC1806 (b) cells at 20x magnification. Image shows blue DAPI-stained nuclei
contrasting green labeled LHRH receptors.
Figure 3 Cytoxic effects of Disorazol-Z and its LHRH conjugate AEZS-125 in (a) HCC1806 and (b) MDA-MB-231; Doxorubicin and and its
cytotoxic conjugate in MDA-MB-231 cells (c) as evaluated by CTB assay.
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and MDA-MB-231 cells was diminished (Figure 4, Table 2),
but at a non-significant level.
Gene silencing of LHRH-R with small interfering RNA to
determine the targeting ability of AEZS-108
Gene silencing with siRNA was performed in order to de-
termine if the inhibitory activity of AEZS-108 is dependent
on the expression of LHRH-R. Cultures were silenced with
siRNA for LHRH-R for 72 hours at which time they were
treated with either 500nM or 1 μM AeZS-108.
Treatment of MDA-MB231 breast cancer cells with
AEZS-108 resulted in 37% and 84% less proliferation
in the 500nM and 1 μM groups, respectively. Transfec-
tion of cells with scrambled human siRNA resulted in
proliferation approximately equal to the controls. Like-
wise, treatment of the cells with only the transfection
reagent resulted in proliferation approximately equal
to the controls. Treatment of LHRH-R silenced cells of
MDA-MB231 resulted in significantly less proliferation
than any of the control groups (P < 0.001) (Figure 5a).
Figure 4 Cytotoxic effects of AEZS-125 with and without pretreatment with LHRH agonist triptorelin, in LHRH- receptor positive TNBC
cells MDA-MB-231 (c) and HCC 1806 (b) and LTK (−) (a) cells the last of which do not express receptors for LHRH.
Table 2 EC50 values in the LHRH receptor expressing HCC1806 and MDA-MB-231 cells and in LHRH-receptor negative
LTK (−) cells subsequent to coincubation with AEZS-125 with and without pretreatment with 100 μM triptorelin
10-minute pretreatment 10-minute treatment EC50 of AEZS-125 (nM)
LTK (−) HCC1806 MDA-MB-231
1% DMSO solvent control AEZS-125 1070.0 ± 351.1 238.1 ± 194.6 392.0 ± 136.6
(n = 3) (n = 3) (n = 4)
100 μM Triptorelin AEZS-125 613.8 ± 217.4 282.7 ± 151.2 499.0 ± 140.1
(n = 3) (n = 3) (n = 4)
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Treatment of HCC1806 breast cancer cells with AEZS-
108 resulted in 50% and 37% less proliferation in the
500 nM and 1 μM groups, respectively. Transfection of
cells with scrambled human siRNA resulted in prolifer-
ation approximately equal to the controls. Likewise,
treatment of the cells with only the transfection reagent
resulted in proliferation approximately equal to the con-
trols. Treatment of LHRH-R silenced cells of HCC1806
resulted in significantly less proliferation than any of the
control groups (P < 0.001) (Figure 5b).
Effects of treatment with AEZS 108 on tumor growth in vivo
In the first experiment, 3 injections of cytotoxic LHRH
analog, AEZS-108, equivalent to 1.45 mg/kg of DOXxHCl,
significantly inhibited the growth of MDA-MB-231 hu-
man TNBC after 14 days compared with the control
group (p < 0.05) and the group treated with equimolar
doses of DOX alone (p < 0.05). The inhibitory effect of
AEZS-108 remained significantly different from con-
trols and DOX until the end of the study on day 28.
Twenty-eight days after the injection of AN-152, tumor
volume was reduced by 59% (p < 0.05) compared to the
control group. An equimolar dose of the cytotoxic radical,
DOX alone, had no significant growth inhibiting effects
(Figure 6).
In the second experiment, administration of 3 doses of
cytotoxic LHRH-analog AEZS-108 equivalent to 1.45 mg/kg
of DOXxHCl, significantly suppressed the proliferation
Figure 5 Colorimetric determination of the proliferation of MDA-MB231 (a) and HCC 1806 (b). Cultures were silenced for 72 hours and treated
with AeZS-108 for an additional 72 hours. Silencing of LHRH-R significantly reduced the inhibitory activity of AEZS-108 in both ell lines (P <0.001, N = 12).
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(p < 0.05) of HCC-1806 human TNBC. Tumor volumes
were significantly lower from treatment day 15 until
the end of the experiment (p < 0.05). Twenty-eight days
after the administration of AN-152, tumor volume was re-
duced by 52% (p < 0.05). An equimolar dose of the cyto-
toxic radical, DOX alone, had no significant effects on any
tumor growth parameters (Figure 7).
Immunohistochemistry and clinical data set
The expression of the LHRH-R by immunohistochemistry
in human triple negative breast tumor samples (n = 69)
was detected in 49% (n = 34) (Figure 8). There was no as-
sociation with grade, tumor size, nodal status or histo-
logical subtype and expression of the LHRH-R (Table 3).
Discussion
In the current study, which analysed the largest patient
group to date, thirty-four out of 69 TNBC patients
(49%) were positive for tumoral LHRH receptors. For
the first time an attempt was made to correlate LHRH-
receptor status with tumor stage and grade, lymph node
status and histology of the tumor. However, no positive
correlation was observed. The patient group was too
small and the follow-up time too short to draw any con-
clusion on whether LHRH receptor status may be of
prognostic use in TNBC.
After showing that LHRH receptors are expressed by
both HCC 1906 and MDA-MB-231 cell lines, we also
demonstrate that LHRH- receptor silencing by siRNA
significantly decreases the cytotoxicity of AEZS-108,
thus providing strong evidence for the receptor mediated
effect of AEZS-108. Accordingly, in our in vivo studies in
these LHRH-receptor positive models of human TNBC,
three injections of AEZS-108 at doses equivalent to
doxorubicin at 1.45 mg/kg significantly suppressed tumor
growth from day 14 of treatment until the end of the
experiment. Unconjugated doxorubicin at equimolar
doses did not show any anti-tumor effect at all. Thus,
we showed that tumoral LHRH-receptors in TNBC can
be successfully targeted with AEZS-108, thus dramatically
increasing the anti-tumor effect of doxorubicin.
In the current study it is also shown, for the first time,
that the novel cytotoxic hybrid molecule AEZS-125,
which is a conjugation of Disorazol-Z to D-Lys6-LHRH,
induces strong cytotoxicity in TNBC cells. Disorazol-Z is
an inhibitor of the mitotic spindle and induces cytotoxic
effects in tumor cells at concentrations in the pico - to
low nanomolar range [21]. Being several hundred times
more potent than doxorubicin, it is therefore an ideal
candidate to use for targeted chemotherapy. The mar-
ginal decrease of the EC 50 after blockade of the LHRH
receptors, which does not occur in LHRH-receptor
negative cells, suggests a receptor mediated uptake of
AEZS-125, similar to the one already demonstrated for
AEZS-108 [22]. However, as it is difficult to conclu-
sively demonstrate receptor targeting in vitro, in vivo
confirmation of targeting is mandatory and animal experi-
ments with AEZS-125 in TNBC are already underway.
LHRH receptors have been found in >50% of human
breast cancer specimens in a non- selected patient cohort
which included ER positive, PR positive, HER2-neu over-
expressing cancers as well as TNBC [20,23]. AEZS-108
has already been tested in nude mice bearing xenografts
of various human breast cancer lines including the LHRH
receptor positive and doxorubicin-resistant human MX-1
breast cancer cell line. AEZS-108 significantly inhibited
the growth of these MX-1 cells while the unconjugated
doxorubicin was ineffective. The expression of mRNA for
HER-2 and HER-3 and the levels of HER-2 and HER-3
proteins was also significantly reduced by the treat-
ment with AEZS-108 [24]. Toxic side effects, such as
leukopenia, were less pronounced in animals which
had been treated with AEZS-108 compared to those
treated with unconjugated doxorubicin [25].
Figure 6 Effects of targeted cytotoxic LHRH analog, AEZS-108,
at doses equivalent to 1.45 mg/kg DOX and the radical DOX
(administered i.v. on days 1, 7, 14) at equimolar doses on the
growth of MDA-MB-231 TNBC xenografted into nude mice
(mean ± se). (* = p < 0.05 two sided Student’s t-test).
Figure 7 Effects of targeted cytotoxic LHRH analog, AEZS-108,
at doses equivalent to 1.45 mg/kg DOX and the radical DOX
(administered i.v. on days 1, 7, 14) at equimolar doses on the
growth HCC-1806 human TNBC (mean ± se). (* = p < 0.05 two
sided Student’s t-test).
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Triple-negative breast cancer represents a subgroup of
breast cancers burdened with a dismal prognosis due to
the lack of specific therapies. In two recent studies in
smaller patient groups LHRH receptors were detected in
about 75% of human specimens [26]. Treatment of triple-
negative, LHRH receptor positive MDA-MB-231, HCC1806
and HCC1937 human breast cancer cells with AEZS-
108 resulted in apoptotic cell death as reflected by
caspase-3 cleavage. The antitumor effects were con-
firmed in vivo, as AEZS-108 significantly inhibited the
growth of the triple-negative breast cancers, HCC1806
and MDA-MB-231, xenografted into nude mice, without
any apparent toxic side effects [1]
Due to good in vivo results in several other tumors,
AEZS-108 has already been tested in Phase I and II
studies in advanced ovarian and endometrial cancers
[27]. In the phase I study the calculated t1/2 and
clearance of AEZS-108 were approximately 2 h and
1 l/min m2, respectively [28]. At the dose levels of
160 and 267 mg/m2, average Cmax values of DOX
ranged from 600 to 700 ng/ml. As expected, average
Cmax and AUC of DOX were closely correlated to the
AEZS-108 levels. In the first Phase II study, which was
performed in collaboration with the German Gynecological
Oncology Group (AGO), 43 patients with taxane-pretreated
platinum-resistant LHRH receptor-positive ovarian cancer
were included (). Partial remission in 5 patients (11.6%) and
disease stabilization in 14 patients (32.6%) for > 12 weeks
was achieved. Median time to progression was determined
to be 3.5 months and median overall survival was
15 months [29].
In the second Phase II study 43 patients with histolog-
ically confirmed, LHRH-R positive, advanced (FIGO III
or IV) or recurrent endometrial cancer were included
[29]. Responses, confirmed by independent review, in-
cluded 2 patients with complete response (CR; 5.1%), 10
patients with partial response (PR; 25.6%), and 17 pa-
tients with stable disease (SD; 43.6%). Based on those
data, an overall response rate (ORR = CR + PR) of 30.8%
and a clinical benefit rate (CBR =CR + PR + SD) of 74.4%
can be estimated. Median time to progression (TTP) and
Figure 8 Immunohistochemical evaluation of LHRH receptor expression: positive cytoplasmic staining reaction (a) and negative
staining reaction (b) in triple negative human breast cancer samples (20×).
Table 3 LHRH-receptor expression of human specimens
of TNBC
LHRH-R negative
samples
LHRH-R positive
samples
absolute percent absolute percent
T
T1 14 40 12 35
T2 17 49 18 53
T3 2 6 1 3
T4 0 0 2 5,9
Unknown 2 5,7 1 2,9
N
+ 11 31 7 21
- 18 51 19 56
unknown 7 20 8 23
Grading
G1 0 0 1 3
G2 10 29 7 21
G3 25 71 26 77
Histology
invasive ductal 29 82,8 28 82,3
invasive lobular 1 2,9 0 0
medullary 5 14,3 6 17,6
The LHRH-receptor positive and negative patient groups are descriptively compared
with respect to size, nodal status, grading and histology of the tumors.
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overall survival (OS) were 7 months and 14.3 months,
respectively. Responses were also achieved in patients
with prior chemotherapy, 1 CR, 1 PR and 2 SDs in 8
patients who had been pretreated with platinum/tax-
ane regimens [30].
In nude mice models AEZS-108 displayed weaker toxic
side effects than equimolar doses of DOX. In particular no
apparent toxic side effects to the pituitary, the heart, or
other organs were observed. This excellent safety profile
was further enhanced in pharmacologic safety studies
evaluating the effects of AEZS-108 on respiratory and car-
diovascular parameters in the dog, as well as in the Irwin
and Rotarod test and in a hexobarbital interaction study.
In these studies no test-item related effects were observed.
In the cardiovascular safety study in beagle dogs, no evi-
dence of QT prolongation was seen at any administered
dose of AEZS-108. No adverse findings were observed in
a local tolerability study in rabbits after intravenous and
intra-arterial infusions of AEZS-108. Perivascular applica-
tion of AEZS-108 induced moderate local inflammatory
reactions. Superior tolerability of AEZS-108 as compared
to DOX was further confirmed in acute and subchronic
toxicity studies in mice, rats and dogs, respectively. In
contrast to DOX, where lymphohistiocytic myocarditis
with intramuscular fibrosis was observed, AEZS-108 did
not induce any cardiotoxicity [22].
Accordingly, in the phase I and both phase II studies,
there was no evidence of cardiotoxicity in serial controls
of LVEF. As the pituitary has receptors for LHRH, pituit-
ary toxicity of AEZS-108 was evaluated in the phase I
study. No relevant effect of AEZS-108 on cortisol levels
was observed in the ACTH stimulation test. Similarly,
there was no effect of AEZS-108 on baseline serum
levels of TSH, T3, and T4 and on the increase in TSH
30 min after stimulation with 200 μg TRH. Thus, at
doses of 267 mg/m2 AES 108 has a favorable safety pro-
file with manageable toxicity [28-30].
This reduction in toxicity during treatment with AEZS-
108, compared to that with free doxorubicin, is likely due
to the homing action of AEZS-108 to cells expressing
LHRH receptors on their cell membrane. In contrast, free
doxorubicin enters the cells by surface diffusion and accu-
mulates in the nucleus independently of the presence of
LHRH receptors on the cell surface.
Conclusion
In conclusion, the current study shows LHRH receptor
expression in 50% of human specimens of TNBC. This
is the largest patient group so far analyzed. LHRH recep-
tor expression did not correlate, however, with known
prognostic factors, such as tumor stage, grade, or nodal
status. In vivo studies with these two human breast can-
cer cell lines confirm that LHRH receptors on TNBC
can be successfully targeted with the cytotoxic LHRH
analog, AEZS 108. Previous work by our group [26], the
study of Foest et al. [1], and the results of the current
study, were the basis for the initiation of a Phase II trial
which evaluates treatment with AEZS −125 in patients
with advanced or metastatic LHRH receptor positive
TNBC, and began patientrecruitment in January 2013.
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